IRADIMED Gestion
Gestion contrôle des critères 4/4
Le PDG IRADIMED est Roger Susi, nommé en Jan2004, a un mandat de 22.42 ans. La rémunération annuelle totale est $ 780.60K, composée du salaire de 49.4% et des bonus 50.6%, y compris les actions et options de la société. détient directement 34.4% des actions de la société, d'une valeur de $ 424.05M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.5 ans et 7 ans.
Informations clés
Roger Susi
Directeur général
US$780.6k
Rémunération totale
| Pourcentage du salaire du PDG | 49.40% |
| Durée du mandat du directeur général | 22.4yrs |
| Propriété du PDG | 34.4% |
| Durée moyenne d'occupation des postes de direction | 4.5yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 7yrs |
Mises à jour récentes de la gestion
Recent updates
IRMD: 2026 Guidance And Bullish Coverage Will Support Further Re Rating
Analysts have nudged their price target on IRADIMED slightly lower, from about $118.67 to $118.00. They are refining assumptions around discount rates, revenue growth, margins and future P/E expectations following recent bullish Street coverage.IRMD: 2026 Dividend And Guidance Will Anchor Bullish Re Rating
Analysts nudged their price targets for IRADIMED higher, with recent Street research citing supportive views on the business. These views help explain the updated fair value of $118.67 along with a slightly adjusted discount rate and forward P/E assumptions.IRMD: 2026 Dividend And Guidance Will Support Bullish Re-Rating
Analysts have trimmed their fair value estimate for IRADIMED from about $120 to roughly $118.67, citing revised assumptions for revenue growth, profit margins and future P/E. At the same time, recent Street research, including fresh bullish initiations and higher price targets, continues to support a constructive view on the stock.IRMD: 2026 Guidance And Dividend Will Support Higher Price Re-Rating
Analysts have lifted their price target on IRADIMED by a double digit dollar amount, citing updated valuation work that reflects refined assumptions, including a fair value of $120, a discount rate of 7.69%, revenue growth of 9.70%, a profit margin of 27.77% and a future P/E of 58.53. Analyst Commentary Recent research points to a tighter alignment between IRADIMED's valuation work and updated assumptions on growth, profitability and the P/E investors may be willing to pay.IRMD: 2026 Guidance And Dividend Will Support Higher P/E Repricing
Narrative Update on IRADIMED The analyst price target on IRADIMED has been raised by $20 to $120. Analysts cite updated valuation work that incorporates a slightly higher discount rate and future P/E assumption, along with recent Street research that supports the new level.IRMD: 2026 Guidance And Dividends Will Support Higher Earnings Multiple
Analysts have lifted their fair value estimate for IRADIMED from $99 to $120, citing updated assumptions around slightly different revenue growth, profit margin expectations, discount rate, and a higher future P/E. These revisions align with recent Street price target increases reported by firms such as Lake Street and Roth Capital.IRMD: Stable Outlook Will Rely On 2026 Guidance And Dividend Support
Analysts have kept their price target for IRADIMED effectively unchanged at $99.00. They cite only marginal tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions rather than any shift in their core view on the company.IRMD: Record Backlog And Raised Guidance Will Support Premium Yet Balanced Outlook
Narrative Update Analysts have nudged their price targets for IRADIMED higher into a US$98 to US$100 range, reflecting updated forward estimates, a record backlog, the recent beat and raise quarter, and expectations tied to the 3870 IV Pump launch. Analyst Commentary Analysts updating their models for IRADIMED are broadly constructive, with recent research focused on how the latest quarter and product pipeline translate into earnings power and valuation support.IRMD: Raised Guidance And Backlog Support Premium While Risks Keep Outlook Balanced
Narrative Update Introduction Analysts have lifted their price expectations for IRADIMED to a range of about $98 to $100, citing higher forward estimates, a record backlog that supports near term visibility, and confidence around the 3870 IV Pump launch as key reasons for the updated targets. Analyst Commentary Recent Street research on IRADIMED reflects a clear tilt toward optimism, with price targets lifted into the high double digits following the latest quarterly update.IRMD: Raised Guidance And Backlog Will Support Premium Amid Execution Risks
Analysts have nudged their average price target on IRADIMED higher, to a level just under $100 per share from the low $90s, citing stronger than expected Q3 results, raised full year guidance, and growing confidence that a robust backlog and upcoming product launches will support sustained growth. Analyst Commentary Bullish analysts highlight that the recent upside surprise on both revenue and earnings, along with raised full year guidance, reinforces a view that IRADIMED is executing ahead of prior expectations and can support a higher valuation multiple.IRMD: Raised Guidance And Strong Backlog Will Maintain Premium Despite Execution Risks
IRADIMED’s analyst price target has been raised from $90 to a range approaching $100 per share. Analysts cite the company’s recent sales and earnings outperformance, increased full-year guidance, and strong prospects from product innovation and backlog growth.IRMD: Raised Guidance And Record Backlog Are Set To Drive Continued Momentum
Analysts have raised their price target for IRADIMED significantly, from $82.50 to $99.00. They cited stronger-than-expected quarterly results, improved guidance, and a robust outlook driven by a growing backlog and product innovation.IRMD: Index Addition and Strong Margins Will Support Measured Upside
Analysts have raised their price target for IRADIMED from $73.50 to $82.50. They cite modest improvements in projected profit margins and valuation multiples as key drivers behind the adjustment.Should You Be Adding IRADIMED (NASDAQ:IRMD) To Your Watchlist Today?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...IRADIMED CORPORATION's (NASDAQ:IRMD) Shares Climb 27% But Its Business Is Yet to Catch Up
Despite an already strong run, IRADIMED CORPORATION ( NASDAQ:IRMD ) shares have been powering on, with a gain of 27% in...IRADIMED's (NASDAQ:IRMD) Profits May Not Reveal Underlying Issues
NasdaqGM:IRMD 1 Year Share Price vs Fair Value Explore IRADIMED's Fair Values from the Community and select yours The...Shareholders Would Enjoy A Repeat Of IRADIMED's (NASDAQ:IRMD) Recent Growth In Returns
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Innovative IV Pumps And Monitor Expansion Set To Spearhead Revenue Surge And Enhance Profit Margins
Introduction of the new 3870 IV pump and expansion in the Monitor business signal potential significant revenue growth and increases in product line revenue.IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals
Despite announcing strong earnings, IRADIMED CORPORATION's ( NASDAQ:IRMD ) stock was sluggish. Our analysis uncovered...If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may...Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?
While IRadimed Corporation ( NASDAQ:IRMD ) might not be the most widely known stock at the moment, it led the NASDAQCM...Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)
Key Insights Using the 2 Stage Free Cash Flow to Equity, IRadimed fair value estimate is US$36.84 IRadimed's US$37.31...At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?
While IRadimed Corporation ( NASDAQ:IRMD ) might not be the most widely known stock at the moment, it led the NASDAQCM...Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$24m |
| Dec 31 2025 | US$781k | US$386k | US$22m |
| Sep 30 2025 | n/a | n/a | US$21m |
| Jun 30 2025 | n/a | n/a | US$21m |
| Mar 31 2025 | n/a | n/a | US$20m |
| Dec 31 2024 | US$690k | US$337k | US$19m |
| Sep 30 2024 | n/a | n/a | US$19m |
| Jun 30 2024 | n/a | n/a | US$19m |
| Mar 31 2024 | n/a | n/a | US$18m |
| Dec 31 2023 | US$643k | US$308k | US$17m |
| Sep 30 2023 | n/a | n/a | US$16m |
| Jun 30 2023 | n/a | n/a | US$15m |
| Mar 31 2023 | n/a | n/a | US$14m |
| Dec 31 2022 | US$586k | US$290k | US$13m |
| Sep 30 2022 | n/a | n/a | US$13m |
| Jun 30 2022 | n/a | n/a | US$12m |
| Mar 31 2022 | n/a | n/a | US$10m |
| Dec 31 2021 | US$615k | US$308k | US$9m |
| Sep 30 2021 | n/a | n/a | US$6m |
| Jun 30 2021 | n/a | n/a | US$5m |
| Mar 31 2021 | n/a | n/a | US$987k |
| Dec 31 2020 | US$435k | US$290k | US$1m |
| Sep 30 2020 | n/a | n/a | US$4m |
| Jun 30 2020 | n/a | n/a | US$5m |
| Mar 31 2020 | n/a | n/a | US$10m |
| Dec 31 2019 | US$488k | US$288k | US$10m |
Rémunération vs marché: La rémunération totale de Roger ($USD 780.60K ) est inférieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 5.26M ).
Rémunération et revenus: La rémunération de Roger a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Roger Susi (73 yo)
Mr. Roger E. Susi serves as President and Chief Executive Officer of IRadimed Corporation since May 28, 2020. He founded IRadimed Corporation in 2004 and has been its Chairman of the Board since June 10, 2...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Founder | 22.4yrs | US$780.60k | 34.4% $ 424.1m | |
| CFO & Corporate Secretary | 4yrs | US$609.99k | 0.066% $ 815.7k | |
| Chief Commercial Officer | 1.6yrs | US$529.36k | 0.0054% $ 66.2k | |
| Vice President of Worldwide Sales & Marketing | 4.9yrs | US$597.28k | pas de données | |
| Executive Vice President of Continuous Improvement & Information Technology | 4yrs | pas de données | pas de données | |
| Controller | 6.4yrs | pas de données | pas de données | |
| Vice President of Research & Development | no data | US$442.20k | pas de données |
Gestion expérimentée: L'équipe de direction de IRMD est considérée comme expérimentée (ancienneté moyenne 4.5 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Founder | 10yrs | US$780.60k | 34.4% $ 424.1m | |
| Director | 7yrs | US$149.91k | 0.23% $ 2.9m | |
| Independent Director | less than a year | US$172.01k | pas de données | |
| Independent Director | 12.4yrs | US$169.91k | 0.16% $ 2.0m | |
| Independent Director | 3.7yrs | US$162.41k | 0.044% $ 539.7k |
Conseil d'administration expérimenté: Les membres du conseil d'administration de IRMD sont considérés comme expérimentés (ancienneté moyenne 7 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/10 17:20 |
| Cours de l'action en fin de journée | 2026/06/10 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
IRADIMED CORPORATION est couverte par 4 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Lawrence Solow | CJS Securities, Inc. |
| Ilya Zubkov | Freedom Broker |
| Frank Takkinen | Lake Street Capital Markets, LLC |